We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 21, 2020

Empagliflozin Improves Cardiovascular and Renal Outcomes in Patients With Heart Failure

Circulation

 

Additional Info

Disclosure statements are available on the authors' profiles:

Circulation
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status — Results From the EMPEROR-Reduced Trial
Circulation 2020 Nov 11;[EPub Ahead of Print], SD Anker, J Butler, G Filippatos, MS Khan, N Marx, CSP Lam, S Schnaidt, AP Ofstad, M Brueckmann, W Jamal, E Bocchi, P Ponikowski, SV Perrone, JL Januzzi, S Verma, M Böhm, JP Ferreira, SJ Pocock, F Zannad, M Packer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading